Summary
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study
evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort
will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with
HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study including
HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who
consent to provide first line outcome data and additional follow up.